LLY · CIK 59478
What Eli Lilly and Company told the SEC could break it.
Eli Lilly's disclosures center on concentration and drug-pricing policy. A significant share of revenue comes from relatively few products — Mounjaro, Zepbound, Verzenio, Trulicity, Taltz and Jardiance each generated over $3 billion — sold through a small set of consolidated distributor entities, concentrating both product and channel risk. Much of the rest is pricing pressure: the expanding 340B discount program (including state mandates to sell to contract pharmacies), possible Medicaid rebate changes, and U.S. efforts to align domestic prices with international benchmarks all stand to raise its discounts or compress prices on a growing share of sales, while certain manufacturing raw materials are procured from a single source.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- 340B program expansion and Medicaid rebate calculation changesmedium
Continued expansion of the 340B program — including state laws mandating 340B sales to contract pharmacies — and possible changes to Medicaid rebate calculations are increasing Lilly's discount/rebate obligations on a growing percentage of sales.
“continued expansion of the 340B program and growth of entities claiming entitlement to 340B pricing, including in ways that may be inconsistent with the statutory scheme and through state laws that purport to mandate 340B sales to contract pharmacies, impacts our revenue on an increasing percentage of sales.”
SEC filing →As of 2026 - U.S. international-reference-pricing / drug-pricing policy effortslow
Lilly flags risk from U.S. government arrangements and broader policy efforts to align domestic pharmaceutical pricing with international benchmarks, which could compress U.S. product pricing.
“Our arrangements with the U.S. government and broader U.S. policy efforts to align domestic pharmaceutical pricing with international benchmarks”
Customer concentration
- revenue concentrated in a few products and consolidated supply-chain entitiesmedium
Lilly derives a significant percentage of total revenue from relatively few products — Mounjaro, Zepbound, Verzenio, Trulicity, Taltz and Jardiance each generated over $3 billion — and sells through consolidated supply-chain (distributor) entities, concentrating both product and channel risk.
“We derived direct product and/or collaboration and other revenues of more than $3 billion for each of Mounjaro, Zepbound, Verzenio, Trulicity, Taltz, and Jardian”
SEC filing →As of 2026
Sole-source dependency
- certain manufacturing raw materials procured from a single sourcemedium
While most principal manufacturing materials come from multiple sources, certain materials are single-sourced, exposing Lilly to interruption or shortage until alternative sources or processes are established.
“Most of the principal materials we use in our manufacturing operations are available from more than one source. However, certain materials are procured from a single source.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
United Therapeutics Corporation
“We rely entirely on Lilly to manufacture Adcirca.”
Cited →Amphastar Pharmaceuticals, Inc.
“we continued to assume distribution responsibilities for BAQSIMI ® from Lilly to our customers in the United States and certain other countries throughout 2024.”
Cited →
Its suppliers
“Under the Lilly Agreement, we granted Lilly an exclusive, worldwide, royalty-bearing license under our technology to research, develop, manufacture, and sell Products directed to up to six mRNA targets.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch